Biogen (BIIB) said Tuesday that it has initiated dosing in the phase 3 Transcend study of felzartamab to treat adult kidney transplant recipients diagnosed with late antibody-mediated rejection, or late AMR.
The biotech company said the study, which will evaluate the efficacy and safety of the investigational drug felzartamab compared to placebo, will enroll approximately 120 kidney transplant recipients with late AMR.
The primary endpoint of study is the percentage of participants who achieve resolution by biopsy of AMR at 6 months.
Price: 149.33, Change: -1.38, Percent Change: -0.92
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.